Rukobia (fostemsavir)

Numéro de dossier de l’APP: 22371

État des négociations:

En négociation

Indication(s):

For use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations

Promoteur/fabricant:

ViiV Healthcare

Numéro de projet de l’ACMTS:

SR0760

Lettre-contrat de l’APP:

2024-02-13

Conclusion du processus de négociation:

Sans objet